Literature DB >> 19429106

The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease.

Catherine Pennington1, Gurjit Chohan, Jan Mackenzie, Mary Andrews, Robert Will, Richard Knight, Alison Green.   

Abstract

The utility of cerebrospinal fluid (CSF) proteins such as 14-3-3, tau protein and S-100b as diagnostic markers in the early stages of sporadic Creutzfeldt-Jakob disease (sCJD) is unclear. We examined the diagnostic value of these CSF proteins in the early stages of sCJD (within 6 weeks of onset of symptoms). Four groups of patients were compared: patients with probable or neuropathologically confirmed sCJD with CSF taken within 6 weeks of onset ('sCJD<6-week group', n=47); patients with CSF taken within 6 weeks of disease onset but with a diagnosis other than CJD ('non-sCJD<6-week group', n=21); patients with neuropathologically proven sCJD where CSF was taken later than 6 weeks after onset ('sCJD>6-week group', n=206); patients with CSF taken later than 6 weeks after onset of symptoms but with a diagnosis other than CJD ('non-sCJD>6-week group', n=166). The sensitivity and specificity of different combinations of neuronal proteins were ascertained. The sensitivities of all three markers were similar and ranged from 96% to 98%. The sensitivity of these markers was greater in the 'sCJD<6-week group' than in the 'sCJD>6-week group'. This may be due to differences in the PRNP codon 129 and PrP isotype distribution between these groups. CSF tau protein had the greatest specificity (82%). We found all three CSF protein markers to be highly sensitive in the early stages of sCJD, with CSF tau protein having the greatest specificity and efficiency. Our findings indicate that CSF protein markers are effective tests in the early stages of sCJD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429106     DOI: 10.1016/j.neulet.2009.02.067

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

1.  CSF metabolites in the differential diagnosis of Alzheimer's disease from frontal variant of frontotemporal dementia.

Authors:  Francesca de Rino; Filippo Martinelli-Boneschi; Francesca Caso; Marta Zuffi; Matteo Zabeo; Gabriella Passerini; Giancarlo Comi; Giuseppe Magnani; Massimo Franceschi
Journal:  Neurol Sci       Date:  2011-11-29       Impact factor: 3.307

2.  Global protein differential expression profiling of cerebrospinal fluid samples pooled from Chinese sporadic CJD and non-CJD patients.

Authors:  Cao Chen; Di Xiao; Wei Zhou; Qi Shi; Hui-Fang Zhang; Jin Zhang; Chan Tian; Jian-Zhong Zhang; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2013-08-04       Impact factor: 5.590

3.  In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification.

Authors:  Emmanuelle Mouton-Barbosa; Florence Roux-Dalvai; David Bouyssié; François Berger; Eric Schmidt; Pier Giorgio Righetti; Luc Guerrier; Egisto Boschetti; Odile Burlet-Schiltz; Bernard Monsarrat; Anne Gonzalez de Peredo
Journal:  Mol Cell Proteomics       Date:  2010-01-21       Impact factor: 5.911

4.  The Levels of Tau Isoforms Containing Exon-2 and Exon-10 Segments Increased in the Cerebrospinal Fluids of the Patients with Sporadic Creutzfeldt-Jakob Disease.

Authors:  Cao Chen; Wei Zhou; Yan Lv; Qi Shi; Jing Wang; Kang Xiao; Li-Na Chen; Bao-Yun Zhang; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2015-07-19       Impact factor: 5.590

5.  Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology.

Authors:  Taim Muayqil; Gary Gronseth; Richard Camicioli
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

6.  CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt-Jakob disease suspected cases with inconclusive 14-3-3 result.

Authors:  M J Leitão; I Baldeiras; M R Almeida; M H Ribeiro; A C Santos; M Ribeiro; J Tomás; S Rocha; I Santana; C R Oliveira
Journal:  J Neurol       Date:  2016-06-29       Impact factor: 4.849

7.  Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease.

Authors:  Sven A Forner; Leonel T Takada; Brianne M Bettcher; Iryna V Lobach; Maria Carmela Tartaglia; Charles Torres-Chae; Aissatou Haman; Julie Thai; Paolo Vitali; John Neuhaus; Alan Bostrom; Bruce L Miller; Howard J Rosen; Michael D Geschwind
Journal:  Neurol Clin Pract       Date:  2015-04

8.  Genomic and post-genomic analyses of human prion diseases.

Authors:  Maurizio Pocchiari; Anna Poleggi; Serena Principe; Silvia Graziano; Franco Cardone
Journal:  Genome Med       Date:  2009-06-22       Impact factor: 11.117

9.  A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD.

Authors:  Swati Haldar; 'alim J Beveridge; Joseph Wong; Ajay Singh; Daniela Galimberti; Barbara Borroni; Xiongwei Zhu; Janis Blevins; Justin Greenlee; George Perry; Chinmay K Mukhopadhyay; Christine Schmotzer; Neena Singh
Journal:  Antioxid Redox Signal       Date:  2013-04-16       Impact factor: 8.401

10.  Unusual features of Creutzfeldt-Jakob disease followed-up in a memory clinic.

Authors:  Agnès Jacquin; Vincent Deramecourt; Serge Bakchine; Claude-Alain Maurage; Florence Pasquier
Journal:  J Neurol       Date:  2014-01-30       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.